Privium Fund Management B.V. Invests $1.24 Million in Cartesian Therapeutics, Inc. $RNAC

Key Points

• Privium Fund Management opened a new position in Cartesian Therapeutics, buying 172,500 shares worth about $1.24 million, leaving Privium with roughly 0.66% of the company as institutional ownership sits near 86.95%.
• Analyst sentiment is mixed-but-leaning-positive: five Buy vs. one Sell give a consensus rating of "Moderate Buy" and an average price target of $34 (top targets include Needham $42 and Wedbush $38).
• Fundamentals remain weak — Cartesian reported a quarterly loss of $1.46 EPS (missing the $0.84 estimate) and just $0.08M in revenue, while the stock trades around $7.39 with a market cap of about $217M and a 52-week range of $5.60–$15.57.

Privium Fund Management B.V. acquired a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 172,500 shares of the company's stock, valued at approximately $1,244,000. Privium Fund Management B.V. owned approximately 0.66% of Cartesian Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Cartesian Therapeutics by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 520,722 shares of the company's stock worth $5,322,000 after purchasing an additional 24,356 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Cartesian Therapeutics by 106.9% during the 3rd quarter. GSA Capital Partners LLP now owns 86,095 shares of the company's stock worth $880,000 after purchasing an additional 44,493 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Cartesian Therapeutics by 114.0% during the 2nd quarter. Marshall Wace LLP now owns 82,630 shares of the company's stock worth $859,000 after purchasing an additional 44,025 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Cartesian Therapeutics during the 3rd quarter worth approximately $259,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Cartesian Therapeutics during the 3rd quarter worth approximately $256,000. 86.95% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on RNAC shares. Wedbush reissued an "outperform" rating and set a $38.00 price objective on shares of Cartesian Therapeutics in a research note on Friday, May 1st. BTIG Research restated a "buy" rating on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Needham & Company LLC restated a "buy" rating and set a $42.00 target price on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Cantor Fitzgerald upgraded shares of Cartesian Therapeutics from a "neutral" rating to an "overweight" rating and set a $16.00 target price on the stock in a research report on Monday, March 9th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Cartesian Therapeutics in a research report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.00.

Cartesian Therapeutics Trading Up 6.6%

NASDAQ:RNAC opened at $7.39 on Wednesday. The firm has a market capitalization of $217.12 million, a price-to-earnings ratio of -1.25 and a beta of 0.58. The firm's fifty day simple moving average is $6.87 and its 200 day simple moving average is $7.24. Cartesian Therapeutics, Inc. has a twelve month low of $5.60 and a twelve month high of $15.57.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.62). The company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.22 million. On average, analysts predict that Cartesian Therapeutics, Inc. will post -3.52 earnings per share for the current year.

About Cartesian Therapeutics

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian's technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian's approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.

Want to see what other hedge funds are holding RNAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.